Palvella Therapeutics, Inc. $PVLA Stock Holdings Lowered by BVF Inc. IL

BVF Inc. IL reduced its stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 24.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 879,009 shares of the company’s stock after selling 282,240 shares during the period. Palvella Therapeutics makes up 3.1% of BVF Inc. IL’s holdings, making the stock its 10th biggest holding. BVF Inc. IL owned about 0.07% of Palvella Therapeutics worth $92,006,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of PVLA. Millennium Management LLC purchased a new stake in Palvella Therapeutics during the 1st quarter worth approximately $7,553,000. Goldman Sachs Group Inc. purchased a new stake in Palvella Therapeutics during the 1st quarter worth approximately $533,000. Geode Capital Management LLC increased its holdings in Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after purchasing an additional 79,787 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the last quarter. Finally, Rhumbline Advisers purchased a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $224,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PVLA shares. Mizuho lifted their price objective on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. BTIG Research lifted their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. HC Wainwright lifted their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Truist Financial set a $210.00 price objective on Palvella Therapeutics in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Palvella Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Trading Up 2.3%

Shares of PVLA opened at $112.63 on Thursday. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -27.01 and a beta of -0.15. The stock has a 50 day moving average of $118.97 and a 200-day moving average of $108.85. Palvella Therapeutics, Inc. has a 52 week low of $20.20 and a 52 week high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, sell-side analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.